MedTrace Logo

Clinical Trial to Evaluate the Safety and Clinical Utility of 18F-FDG Produced by the Molecular Imaging and Research Centre of Nova Scotia

NCT01136720 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9463

Last updated 2024-08-21

No results posted yet for this study

Summary

18F-FDG produced in the MIRC NS has a similar safety profile to the same compound utilized elsewhere in that no significant adverse events will occur during observation of the patients for 2 1/2 hours post injection of the tracer. It is also hypothesized that as this FDG produced by similar methodology and its quality assurance assessed as in another jurisdictions will have similar performance parameters in patients with focal lung pathology to that previously determined.

Conditions

  • 18FDG

Sponsors & Collaborators

  • Nova Scotia Health Authority

    lead OTHER

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-19
Primary Completion
2017-04-18
Completion
2017-04-18

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136720 on ClinicalTrials.gov